\n<\/p>\n
As the\u00a0World Health Organization<\/em>\u00a0(WHO) finalized a historic Pandemic Agreement intended to \u201cstrengthen global pandemic preparedness,\u201d the U.S. government, under President Donald Trump\u2019s second term, delivered a pointed rejection of the deal.\u00a0Department of Health and Human Services<\/em>\u00a0Secretary\u00a0Robert F. Kennedy Jr. urged a \u201creboot\u201d of global health institutions, casting the WHO as a bureaucratic and politically compromised entity<\/a>\u00a0following the Trump administration\u2019s official withdrawal from the organization. The move has deepened a rift between the U.S. and its international health partners, while fueling debates about sovereignty, transparency and the lessons of the COVID-19 pandemic.<\/p>\n The Pandemic Agreement, formally adopted by the 78th World Health Assembly on May 20, aims to \u2018standardize global cooperation\u2019 in responding to future pandemics. However, the U.S. decision to exit the WHO \u2014 one year after President Trump signed an executive order formally ending U.S. membership \u2014 has cast doubt on its implementation. Kennedy called the agreement a \u201cfailure to reform\u201d systemic\u00a0flaws highlighted during the COVID-19 pandemic<\/a>, accusing the WHO of kowtowing to political pressures and failing to address its past missteps.<\/p>\n Kennedy\u2019s remarks, delivered via video at the WHO Assembly, drew widespread attention for their blunt critique of the global body. \u201cThe WHO has become mired in bureaucratic bloat, entrenched paradigms, conflicts of interest and international power politics,\u201d he said, adding that the U.S. would no longer participate in an organization that\u00a0\u201cforgot its accountability to citizens over corporate or transnational interests.\u201d<\/a><\/p>\n The focal point of dissent was the Pandemic Agreement, or WHO CA+, which\u00a0mandates member nations to reserve 20% of pandemic vaccine and treatment supplies for distribution to poorer countries during emergencies<\/a>. While WHO Director-General Tedros Adhanom Ghebreyesus hailed the deal as a \u201cvictory for public health,\u201d Kennedy labeled it a gamble: \u201cIt locks in all the dysfunctions of the WHO pandemic response.\u201d<\/p>\n The U.S. withdrawal stems in part from\u00a0how the WHO\u00a0mishandled the early stages of the pandemic by deferring to Chinese authorities, including promoting the Wuhan wet market theory<\/a>\u00a0over a lab-leak origin. Kennedy reiterated this stance during his address, stating the WHO had promoted \u201cthe fiction that COVID originated from bats or pangolins,\u201d rather than acknowledging evidence of a potential leak from the Wuhan Institute of Virology.<\/p>\n Despite assurances from the WHO that the Pandemic Agreement contains no provisions to \u201cdirect, order, or impose requirements\u201d on member nations \u2014 including vaccine mandates or lockdowns \u2014 health freedom advocates argue the text still risks overreach. Dan Astin-Gregory of Free Humanity acknowledged the inclusion of sovereignty protections as a \u201csubtle victory\u201d but warned the pact perpetuates problematic frameworks. \u201cIt normalizes the WHO\u2019s dysfunctional approach,\u201d he said, referencing the organization\u2019s reliance on pharmaceutical partnerships and lack of accountability.<\/p>\n Epidemiologist Nicolas Hulscher, writing in a Substack post, described provisions for equitable vaccine distribution as a \u201cpressure\u201d tactic to align national laws with\u00a0global directives<\/a>. He also cautioned the agreement could enable \u201cfast-track approvals\u201d for experimental vaccines \u2014 a process widely criticized during the rollout of mRNA shots in 2020\u20132021. Dr. Maria Hubmer-Mogg, a physician and activist, added that the WHO\u2019s one-size-fits-all approach disregards localized health needs and undermines doctor-patient relationships.<\/p>\n Proponents of the agreement, however, argue its importance lies in its structure. The deal, they say, ensures countries collaborate on sharing virus data and resources, while the new Pathogen Access and Benefit Sharing (PABS) system aims to accelerate equitable distribution of treatments. Suerie Moon, a global health governance expert, conceded finance remains a major challenge: with the U.S. withholding contributions, \u201cthe Achilles heel is funding to make these systems work.\u201d The WHO has already instituted budget cuts amid anticipated losses of $900 million annually without U.S. dues.<\/p>\n The U.S. rejection of the WHO CA+ has introduced uncertainty into global health cooperation, even as the Trump administration vows to\u00a0boost pandemic preparedness<\/a>\u00a0domestically. Kennedy pledged increased focus on addressing chronic diseases \u2014 a shift from past priorities \u2014 but offered little clarity on how the U.S. will engage with global health crises without WHO collaboration.<\/p>\n Beate Sibylle Pfeil, a German attorney, noted the 11 abstentions during the agreement\u2019s adoption signals a weakening consensus. \u201cStates are now critical of the WHO, but still hesitant to speak up,\u201d she said. Meanwhile, Astin-Gregory speculated the U.S. withdrawal could catalyze alternatives: \u201cWe might see a parallel organization emerging from the bottom up\u2014a competitive pressure to reform or replace the WHO.\u201d<\/p>\n The Pathogen Access and Benefit Sharing system negotiations, due for finalization over the next two years, will test the agreement\u2019s viability. Independent journalist James Roguski viewed this phase as an opportunity to scrutinize ties to Big Pharma: \u201cIt\u2019s an attempt to expand manufacturing and distribution networks for pharmaceutical giants,\u201d he said.<\/p>\n As the Pandemic Agreement proceeds toward ratification, the world faces a pivotal moment in how it confronts future crises. With the U.S. \u2014 historically a health aid linchpin \u2014 on the sidelines, the WHO\u2019s future remains uncertain. For Kennedy, the answer is systemic overhaul: \u201cThe failures of COVID demand more than tweaks.\u201d Yet without U.S. participation or resources, the pact\u2019s effectiveness hinges on whether fractured global politics can yield a unified resolution.<\/p>\n The next steps will shape both global health architecture and the much-debated balance between international cooperation and national sovereignty. With partisan lines and distrust entrenched, one truth remains: The next pandemic will test both the agreement and the institutions built to withstand it.<\/p>\n Sources for this article include:<\/strong><\/p>\nU.S. rejection highlights WHO criticisms<\/h4>\n
Sovereignty and subversion: Critics row over Pandemic\u00a0Agreement\u00a0details<\/h4>\n
The road ahead: A fractured multilateral framework?<\/h4>\n
A global health crossroads: Rebuilding trust amid divided priorities<\/h4>\n